Clinical trials: Amyotrophic Lateral Sclerosis, Familial
Familial Amyotrophic Lateral Sclerosis
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study
By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress".
- Trial name
- TRANSLATE (NCT03707795)
- Testing
- Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Edward Kasaraskis
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Amyotrophic Lateral Sclerosis (ALS)
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis
The purpose of this research study is to evaluate tau distribution in the brain of subjects with: ALS caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic…
- Trial name
- T807ALS (NCT02414230)
- Testing
- Drug: F 18 T807
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Tetraplegia
NeuroCognitive Communicator: Safety Study
Individuals suffering from tetraplegia as a result of cervical spinal cord injury, brainstem stroke, or amyotrophic lateral sclerosis (ALS) cannot independently perform tasks of daily living.
- Trial name
- NCC-1701 (NCT03100110)
- Testing
- NeuroCognitive Communicator
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ottawa Hospital Research Institute
Sporadic and Familial Amyotrophic Lateral Sclerosis
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.
- Trial name
- FB1006 (NCT05923905)
- Testing
- FB1006
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University Third Hospital
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania